SYMPTOM BURDEN OF PATIENTS WITH IGA NEPHROPATHY IN A REAL WORLD SETTING ACROSS GEOGRAPHIES

WCN23-0369
Chronic Kidney Disease, Hypertension, Diabetes and CVD
Nephrotic Syndrome
 
 
 
 
SYMPTOM BURDEN OF PATIENTS WITH IGA NEPHROPATHY IN A REAL WORLD SETTING ACROSS GEOGRAPHIES
Lafayette, R.(1)*;Smeets, S.(2);Kattlun, J.(2);George, A.T.(3);Aldworth, C.(4);Proudfoot, C.(5);Wang, W.(4);De Courcy, J.(6);Yao, L.(7);Roccatello, D.(8);
ie: Azwin Z.1, Siti Y.1, John D.2
(1)Stanford University Of Medicine, Nephrology, Stanford, United States;(2)Novartis Pharma Ag, Global Medical Affairs, Basel, Switzerland;(3)Novartis Healthcare Pvt. Ltd., Value And Access, Hyderabad, India;(4)Novartis Pharmaceuticals Corporation, Medical, New Jersey, United States;(5)Novartis Pharma Ag, Global Heor, Basel, Switzerland;(6)Adelphi Real World, Real World, England, United Kingdom;(7)The First Hospital Of China Medical University, Nephrology, Shenyang, China;(8)University Of Turin, Nephrology, Turin, Italy;
https://storage.unitedwebnetwork.com/files/1041/b07ce5a8ea299d165e552a3877be9819.pdf
 
if any